CD274 and neoplasm: Immune checkpoint blockade therapy, utilizing neutralizing monoclonal antibodies to inhibit the interaction between PD-1 and PD-L1 and reinvigorate T cell antitumor activity, has emerged as a promising therapeutic strategy, demonstrating significant efficacy in treating various tumor types [27–29].